
The subcutaneous dose had comparable efficacy to intravenous dosing while enhancing patient convenience in non–small cell lung cancer, explains Nicolas Girard, MD, PhD.
Nicolas Girard, MD, PhD, is head of the medical oncology department at Institut Curie in France.

The subcutaneous dose had comparable efficacy to intravenous dosing while enhancing patient convenience in non–small cell lung cancer, explains Nicolas Girard, MD, PhD.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
